The European Commission's Directorate-General for Competition accepted notification of the SK Capital / Swixx Biopharma merger on March 9, 2026, triggering review under the EU Merger Regulation (Council Regulation 139/2004). The transaction involves companies operating in wholesale pharmaceutical and medical goods distribution (NACE G.46.46). The Commission issued a decision under Article 6(1)(b) on March 31, 2026, indicating clearance under the simplified procedure.

The provisional deadline for the Commission's decision is April 16, 2026. Parties to mergers meeting the EU thresholds should ensure timely notification and monitor the case tracker for final clearance before completing the transaction. The case reference is M.12332 and the decision was published in the Official Journal as OJEU C/2026/1801.